Takase Z, Fujiwara M, Komoto Y, Seto M, Shirafuji H, Shimizu T, Ishikawa M, Ichinoe K, Kutsuzawa T, Uno Y
Jpn J Antibiot. 1985 Aug;38(8):2313-37.
Fundamental and clinical studies on a new cephalosporin antibiotic, cefpiramide (CPM), was carried out under a joint study program, in order to evaluate the usefulness of the drug in treating infection of the female genital organs. The results obtained were as follows: CPM was readily transported to female genital organ tissues, and the concentrations of the drug exceeded 35 micrograms/g in various organ tissues in about 1 hour, following intravenous injection of 1 g. A level of more than 2 micrograms/g was maintained even 14 hours after the injection. The transport of CPM to various tissues was also studied following intravenous drip infusion of 1 g for 1 hour. The concentrations in tissues were slightly low but similar to those following intravenous injection. The peak concentration of the drug in the dead space exudate was 3.1-20.4 micrograms/ml, following intravenous injection and intravenous drip infusion of 1 g. The MIC80 of CPM were 3.13-12.5 micrograms/ml against S. aureus, Klebsiella sp., P. mirabilis and P. aeruginosa. Clinical effects of CPM were analyzed in 158 patients, including 56 cases with intrauterine infection, 37 cases with intrapelvic infection, 22 cases with external genital infection, 31 cases with adnexitis, 6 cases with postoperative wound infection and 6 cases with other infections. Excellent response was seen in 28 cases (17.7%), good response in 120 (75.9%) poor response in 10 (6.3%). The rate of response was calculated as 93.7%. Safety of the drug was analyzed in 258 patients, and side effects occurred in 4 (1.6%). Of these 4 patients, rash was in 1 patient, heat sensation in 1 patient, nausea in 1 patient and rash accompanying edema in 1 patient. Abnormal values in clinical laboratory findings were seen in 7 patients. Elevations of transaminase were seen in 5 patients and decrease of platelet was seen in a patient, and then elevations of transaminase with decrease of platelet was seen in a patient, and no other changes of particular note appeared.
在一项联合研究项目中,对一种新型头孢菌素抗生素头孢匹胺(CPM)进行了基础和临床研究,以评估该药物在治疗女性生殖器官感染方面的有效性。获得的结果如下:静脉注射1g后,CPM易于转运至女性生殖器官组织,约1小时后各器官组织中的药物浓度超过35微克/克。注射后14小时仍维持在2微克/克以上的水平。静脉滴注1g持续1小时后,也对CPM在各种组织中的转运进行了研究。组织中的浓度略低,但与静脉注射后的浓度相似。静脉注射和静脉滴注1g后,死腔渗出液中药物的峰值浓度为3.1 - 20.4微克/毫升。CPM对金黄色葡萄球菌、克雷伯菌属、奇异变形杆菌和铜绿假单胞菌的MIC80为3.13 - 12.5微克/毫升。对158例患者分析了CPM的临床疗效,其中包括56例宫内感染、37例盆腔内感染、22例外阴感染、31例附件炎、6例术后伤口感染和6例其他感染。28例(17.7%)反应极佳,120例(75.9%)反应良好,10例(6.3%)反应不佳。反应率计算为93.7%。对258例患者分析了该药物的安全性,4例(1.6%)出现副作用。在这4例患者中,1例出现皮疹,1例有热感,1例恶心,1例皮疹伴水肿。7例患者临床实验室检查结果出现异常值。5例患者转氨酶升高,1例患者血小板减少,1例患者转氨酶升高伴血小板减少,未出现其他特别值得注意的变化。